The study initially aims to enroll 20,000 people who are currently, or were previously, in intensive care with severe COVID-19 disease, as well as 15,000 infected individuals who suffered only mild or moderate symptoms.
New browser tool Genebass allows researchers and clinicians to search for rare genetic variants linked to diseases.
Merck and Orna Therapeutics signed a collaboration agreement to discover, develop, and commercialize multiple programs around Orna's novel circular RNA (oRNA) technology.
University of Michigan (U-M) Life Sciences Institute scientists have discovered a hormone secreted by fat cells can prevent the growth of liver tumors in mice.
Precision oncology therapy pralsetinib achieved a disease control rate of 83% and an overall response rate of 57% in a Phase I/II trial.
The Mount Sinai Million Health Discoveries Program has just been launched by Mount Sinai Health System with the Regeneron Genetics Center. The program aims to enroll one million Mount Sinai patients over a five-year period.